NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, both dates inclusive (the “Class Period”), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased Baxter common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, of the December 15, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Baxter common stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To join the class action, interested parties can visit the provided link or contact the law firm for more information [3][6] - A lead plaintiff is required to file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [5] - Specific issues included malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, which resulted in injuries and deaths [5] - Baxter's inadequate responses to these defects and the potential halting of new sales of the pumps contributed to misleading statements regarding the product's safety and sales prospects [5]

Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025, and investors who purchased Baxter common stock during this time may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][4]. - Investors wishing to serve as lead plaintiffs must file a motion with the court by December 15, 2025, to represent other class members in the litigation [4]. Group 2: Allegations Against Baxter - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which caused malfunctions that posed serious risks to patients [6]. - Specific issues cited include underinfusion, overinfusion, and complete non-delivery of fluids, along with inadequate remedial measures taken by Baxter despite being notified of multiple device malfunctions and associated injuries [6]. - The lawsuit claims that Baxter's statements regarding the safety, efficacy, and sales prospects of the Novum LVPs were materially false and misleading, leading to investor damages when the true details became public [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions of dollars for investors [5]. - The firm has been recognized for its leadership in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 alone [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - Investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [6]. - Specific claims include that Baxter was aware of multiple malfunctions and injuries related to the Novum LVP, and that their remedial measures were inadequate [6]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and significant recoveries for investors in recent years [5]. - The firm has been recognized for its performance in the field, being ranked highly for the number of securities class action settlements [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - Investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients, including malfunctions and potential injuries or deaths [6]. - The lawsuit claims that Baxter's attempts to address these defects were inadequate, and as a result, there was a heightened risk of customers removing the Novum LVPs from service and halting new sales [6]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - Rosen Law Firm has a history of successful settlements in securities class actions, including a record settlement against a Chinese company and significant recoveries for investors in previous years [5]. - The firm has been recognized for its achievements in the field, including being ranked No. 1 for securities class action settlements in 2017 and securing over $438 million for investors in 2019 [5].

Core Viewpoint - Rosen Law Firm is urging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action related to stock purchases made between February 23, 2022, and July 30, 2025 [2][3]. Group 1: Class Action Details - Investors who purchased Baxter common stock during the specified Class Period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients, including malfunctions that could result in underinfusion, overinfusion, or non-delivery of fluids [6]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of product recalls and halting new sales [6]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - The Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Baxter common stock between February 23, 2022, and July 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 15, 2025 deadline to serve as lead plaintiff, representing other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to malfunctions and posed serious risks to patients [5]. - Specific claims include that Baxter was aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of product recalls and halting new sales [5]. - The lawsuit asserts that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, resulting in investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements achieved [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - Investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must move the court by December 15, 2025 [4]. - The lawsuit alleges that Baxter misled investors regarding the safety and efficacy of its Novum IQ Large Volume Pump, which suffered systemic defects leading to serious patient risks [6]. Group 2: Allegations Against Baxter - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion and overinfusion, exposing patients to serious injury or death [6]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to continued harm [6]. - The allegations suggest that Baxter's statements about the product's safety, efficacy, and sales prospects were materially false and misleading, resulting in investor damages when the truth was revealed [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [5]. - The firm has been ranked highly for its number of securities class action settlements and has recovered hundreds of millions of dollars for investors [5]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing shareholder interests [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - Investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by December 15, 2025, to represent other class members [4][6]. Group 2: Allegations Against Baxter - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which caused malfunctions that posed serious risks to patients [6]. - Specific issues included underinfusion, overinfusion, and complete non-delivery of fluids, along with inadequate responses to reported malfunctions and injuries [6]. - The lawsuit claims that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, leading to investor damages when the truth was revealed [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [5]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, of the December 15, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Baxter common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The deadline to move the Court to serve as lead plaintiff is December 15, 2025, with the lead plaintiff acting on behalf of other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field [4] Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [5] - Specific claims include that Baxter was aware of multiple device malfunctions and that its remedial measures were inadequate, resulting in a heightened risk of product recalls and sales pauses [5] - The lawsuit asserts that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, causing investor damages when the truth was revealed [5]